Vitae Pharma Cash Flow - Quarterly (NASDAQ:VTAE)

Add to My Stocks
$21 $0 (0%) VTAE stock closing price Oct 25, 2016 (Closing)

The Vitae Pharma cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. This report provides details about cash inflows and outflows due to the company's business and investment activities, and summarize cash outflows for a given quarter. For Vitae Pharma profits one has to check the income statement and for Vitae Pharma debt one has to check the balance sheet. This statement can tell if a company is running out of money while still being profitable and is useful in Vitae Pharma stock analysis. Vitae Pharma had a negative net income cash flow of $-20.41M till this quarter of 2016 Q2. This report is very useful in measuring the short term viability of a company. The cash from operating activities for Vitae Pharma is $ 2016 Q2, which saw a decrease from previous quarter.

View and download details of Vitae Pharma cash flows for latest & last 40 quarters
show more
Fiscal year is Jan - Dec2016 Q22016 Q12015 Q4
Net Income Cash Flow
-20.41M-10M-43.98M
Depreciation Depletion Amortization Cash-Flow---
Net Increase (Decrease) in Assets Liabilities-0.49M-1.31M3.16M
Cash From (used in) Discontinued Operations---
Other Adjustments Net1.47M-2.51M
Net Cash from (used by) Operating Activities
-19.32M-10.53M-38.03M
Increase (Decrease) in Prop Plant And Equipment-0.09M-0.02M-0.29M
Acquisition Disposition of Subsidiaires---
Increase (Decrease) in Investments-5.65M19.51M-11.76M
Other Cash Inflow (Outflow) from Investment Activities---
Net Cash from (used by) Investment Activities
-5.75M19.48M-12.06M
Issuance (Purchase) of Equity Shares38.02M37.81M37.93M
Issuance (Repayment) of Debt Securities---4.93M
Increase (Decrease) in Bank & Other Borrowings---
Payment of Dividends & Other Cash Distributions---
Other Cash from (used by) Financing Activities-0.57M-0.19M-0.62M
Net Cash from (used by) Financing Activities
37.45M37.62M32.37M
Effect of Exchange Rate Changes on Cash---
Net Change in Cash & Cash Equivalents
12.37M46.57M-17.72M
Cash & Equivalents at Beginning of Year---
Cash & Equivalents at Year End24.14M58.35M11.77M
All figures in USD. M: Millions of USD, B: Billions of USD.

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The Vitae Pharma stock price history and Vitae Pharma stock comparison chart inevitably reflect its cash flow situation.

  • Vitae Pharma had a Net Change in Cash and Cash Equivalents of $12.37M in the latest quarter 2016 Q2. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Vitae Pharma stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Vitae Pharma decreased its cash from operating activities to $-19.32M till 2016 Q2. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc., and was $-5.75M for VTAE till last quarter 2016 Q2 report.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $37.45M for Vitae Pharma. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.

Quarterly Cash Flow Statements For Vitae Pharmaceuticals Inc Peers

Biogen Inc cash flow, ChemoCentryx cash flow, GlycoMimetics cash flow, Merck cash flow